Upcoming & Enrolling Pediatric Cystic Fibrosis Clinical Trials
The studies listed below will soon be or are currently enrolling participants. Our list of upcoming studies is constantly evolving. Please contact our research team to learn about clinical trials in our pipeline that may not be listed here!
To learn more about upcoming clinical trials in CF, visit the Cystic Fibrosis Foundation’s Clinical Trials Finder.
Last updated October 13th, 2023.
This is an accordion element with a series of buttons that open and close related content panels.
CHEC-OB-17 | Sweat Chloride Collection
“This study is taking place at multiple care centers across the U.S. It will look at sweat chloride concentration in people who are currently taking CFTR modulators.” – CFF Trial Finder Profile
Principal Investigator: Hara Levy, MD
Lead Research Coordinator: Melanie Nelson
Key Inclusion Criteria:
– Enrolled in CFF Patient Registry
– On current modulator for > 90 days
Time Commitment: One time sweat test.
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
VX22-CFD-017 | Questionnaires for CF patients and their caregivers
“A non-interventional study evaluating the impact of ELX/TEZ/IVA initiation on children and caregivers of children with CF.”
Principal Investigator: Hara Levy, MD
Lead Research Coordinator: Melanie Nelson
Key Inclusion Criteria:
– Patient with CF is 3-5 years old at enrollment
– Caregiver must be >18 years of age and is the primary person responsible for CF patient
– Both CF patient and caregiver are willing and able to complete questionnaires provided
Time Commitment: One enrollment visit prior to initiating TRIKAFTA, then completion of questionnaires 6 and 12 months after.
See CFF Trial Finder profile *not yet available.
See ClinicalTrials.gov profile *not yet available.
Ongoing Pediatric Cystic Fibrosis Clinical Trials
The clinical trials listed below are currently ongoing and are no longer accepting new participants. Our studies are both investigational and observational. We enjoy working with families from all around the Midwest. Please contact our research team to learn about clinical trials in our pipeline that may not be listed here!
To learn more about upcoming clinical trials in CF, visit the Cystic Fibrosis Foundation’s Clinical Trials Finder.
Last updated June 15th, 2023.
This is an accordion element with a series of buttons that open and close related content panels.
BEGIN-OB-19 Part B | Observing CFTR modulators in infants and young children
“This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.” – CFF Trial Finder Profile
Principal Investigator: Christina Barreda, MD
Lead Research Coordinator: Melanie Nelson
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
PROMISE-OB-18 Pediatric Cohort | Observational Trikafta Study
“This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinator: Nikki Cole
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
VX21-121-105 Part B1 | Once a Day New Modulator
“This interventional open-label study will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.” – CFF Trial Finder Profile
Principal Investigator: Hara Levy, MD
Lead Research Coordinator: Megan Devereaux
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
VX22-121-106 | Open Label Once a Day New Modulator
“The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).” – ClinicalTrials.gov Profile
Principal Investigator: Hara Levy, MD
Lead Research Coordinator: Megan Devereaux
See ClinicalTrials.gov profile here.